Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cowen Maintains Bullish View on Amgen (AMGN) Following Panel Repatha In Familial Hypercholesterolemia
June 11, 2015 7:13 AM EDTCowen analyst Eric Schmidt reiterating an Outperform rating and $189 price target on Amgen (NASDAQ: AMGN) after an FDA panel backed Repatha in familial hypercholesterolemia.
Analyst Erich Schmidt commented, "The FDA's EMDAC panel recommended Repatha be approved for HoFH (15:0 vote) and one more additional very... More
Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing
June 11, 2015 6:43 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and $195 price target on Amgen (NASDAQ: AMGN) after an FDA panel recommended approval of Repatha, as expected.
Yang commented, "Positive panel votes were widely expected (11-4 in favor for non-HoFH high-risk pts;... More
